Kochhäuser Simon, Alipour Pouria, Haig-Carter Tanjah, Trought Kathleen, Hache Philip, Khaykin Yaariv, Wulffhart Zaev, Pantano Alfredo, Tsang Bernice, Birnie David, Verma Atul
Southlake Regional Health Centre, Newmarket, Ontario, Canada.
Arrhythmia Service, Division of Cardiology, University of Ottawa Heart Institute, Ontario, Canada.
J Cardiovasc Electrophysiol. 2017 Mar;28(3):273-279. doi: 10.1111/jce.13138. Epub 2017 Jan 11.
Because of the unclear prognostic effects of ablation of atrial fibrillation (AF), oral anticoagulation (OAC) is often continued after ablation even in asymptomatic patients. We sought to determine the frequency of stroke and AF recurrence in patients on and off therapeutic OAC 1 year after a successful AF ablation.
Patients that underwent AF ablation and were free of AF 12 months after ablation were selected from our AF database. During follow-up (FU), patients were screened for recurrence of AF, changes in OAC or antiarrhythmic medication, and the occurrence of stroke or transient ischemic attack (TIA). A total of 398 patients (median age 60.7 years [50.8, 66.8], 25% female) were investigated. The median duration of FU was 529 (373, 111,3.5) days. OAC was discontinued in 276 patients (69.3%). During FU, 4 patients (1%) suffered from stroke and 55 patients (13.8%) experienced a recurrence of AF. Persistent AF was significantly associated with a greater chance of AF recurrence (49.1% vs. 26.8%; P = 0.001). Neither CHADS nor CHA2DS2-VASc-Score nor recurrence of AF were significantly different in patients with or without stroke. There was a trend toward a higher percentage of coronary artery disease among patients that experienced stroke (50% vs. 10%; P = 0.057).
The overall risk of stroke and AF recurrence is low in patients with a recurrence free interval of at least 12 months after AF ablation. Of note, recurrence of AF was not associated with a higher risk of stroke in our study population.
由于房颤(AF)消融的预后影响尚不清楚,即使是无症状患者,消融术后通常也会继续口服抗凝药(OAC)治疗。我们试图确定成功进行房颤消融术后1年接受和未接受治疗性OAC治疗的患者中中风和房颤复发的频率。
从我们的房颤数据库中选取接受房颤消融且消融后12个月无房颤的患者。在随访(FU)期间,对患者进行房颤复发、OAC或抗心律失常药物变化以及中风或短暂性脑缺血发作(TIA)发生情况的筛查。共调查了398例患者(中位年龄60.7岁[50.8, 66.8],25%为女性)。中位随访时间为529(373, 111,3.5)天。276例患者(69.3%)停用了OAC。在随访期间,4例患者(1%)发生中风,55例患者(13.8%)经历房颤复发。持续性房颤与房颤复发的可能性显著相关(49.1%对26.8%;P = 0.001)。有或无中风的患者在CHADS、CHA2DS2-VASc评分或房颤复发方面均无显著差异。中风患者中冠状动脉疾病的比例有升高趋势(50%对10%;P = 0.057)。
房颤消融术后无复发间隔至少12个月的患者中风和房颤复发的总体风险较低。值得注意的是,在我们的研究人群中,房颤复发与中风风险升高无关。